Abaloparatide

What is Abaloparatide?

Abaloparatide is a synthetic 34-amino-acid analog of the N-terminal portion of parathyroid hormone-related protein (PTHrP 1-34). It is FDA-approved (2017) and marketed as Tymlos for the treatment of postmenopausal women with osteoporosis at high risk of fracture, and was subsequently approved for men with osteoporosis. Like teriparatide, abaloparatide is anabolic — it actively stimulates new bone formation rather than simply slowing bone loss — but it is engineered to bind the PTH1 receptor with a different conformational preference, which translates in clinical data to comparable or superior BMD gains with somewhat less transient hypercalcemia.

What Abaloparatide Is Investigated For

Abaloparatide is investigated and FDA-approved for postmenopausal women with osteoporosis at high fracture risk and, following the ATOM trial, for men with osteoporosis. The strongest evidence is the pivotal Phase 3 ACTIVE trial (Miller et al., JAMA 2016), which randomized 2,463 postmenopausal women to abaloparatide 80 mcg daily, open-label teriparatide 20 mcg daily, or placebo for 18 months. Abaloparatide reduced new morphometric vertebral fractures and non-vertebral fractures versus placebo, with BMD gains at the lumbar spine, total hip, and femoral neck that were at least comparable to — and at several timepoints greater than — teriparatide, alongside a lower incidence of treatment-emergent hypercalcemia. The ACTIVExtend trial (Cosman et al., Mayo Clin Proc 2017) showed that transitioning from abaloparatide to alendronate preserved and extended the fracture-risk reduction for up to two additional years. The molecular rationale is a selectivity difference at the PTH1 receptor (RG-conformation bias) that produces more transient cAMP signaling and — mechanistically — a cleaner anabolic window with less osteoclast activation than PTH 1-34. The honest caveats are familiar to the PTH-agonist class: BMD gains are lost rapidly after discontinuation unless an antiresorptive consolidation phase follows, daily-injection adherence is real-world challenge, the labeled boxed warning for osteosarcoma risk (based on rat carcinogenicity, not human signal) was removed in 2022 alongside teriparatide's, and head-to-head fracture outcomes against teriparatide and romosozumab remain limited to indirect comparisons.

History & Discovery

Abaloparatide was developed by Radius Health (Waltham, Massachusetts; the asset has since passed through subsequent corporate transactions) as an engineered analog of parathyroid hormone-related protein (PTHrP 1-34). The mechanistic origin story starts in the 1980s with the identification of PTHrP as the peptide responsible for humoral hypercalcemia of malignancy; PTHrP shares significant N-terminal homology with PTH and acts on the same PTH1 receptor, but has distinct physiological roles (cartilage and developmental biology, lactational calcium mobilization, vascular smooth muscle). The therapeutic hypothesis behind abaloparatide was that intentional substitutions in the PTHrP 1-34 sequence could bias PTH1R binding toward the RG (rapid, transient) signaling conformation rather than the R0 (prolonged) conformation favored by PTH 1-34. The Hattersley et al. Endocrinology 2016 paper established this molecular behavior in detail: abaloparatide produces more transient cAMP responses at PTH1R than PTH 1-34, which was hypothesized to translate to a cleaner anabolic effect with less osteoclast activation and less sustained hypercalcemia. The pivotal Phase 3 ACTIVE trial (Miller et al., JAMA 2016) randomized 2,463 postmenopausal women with osteoporosis at high fracture risk to daily subcutaneous abaloparatide 80 mcg, open-label teriparatide 20 mcg, or placebo for 18 months. Abaloparatide reduced the incidence of new morphometric vertebral fractures and non-vertebral fractures versus placebo, with BMD gains at the lumbar spine, total hip, and femoral neck that were comparable to or greater than teriparatide and with a lower rate of treatment-emergent hypercalcemia. Post-hoc responder analyses (Cosman et al., Bone 2018) showed a significantly greater proportion of abaloparatide patients achieved >3% BMD gains at each timepoint than patients on teriparatide. The FDA approved Tymlos on April 28, 2017 for the treatment of postmenopausal women with osteoporosis at high risk of fracture. The original label included a boxed warning for osteosarcoma risk (based on the Fischer 344 rat carcinogenicity data shared with teriparatide) and a cumulative lifetime use cap of 2 years; the FDA removed both the boxed warning and the lifetime cap in 2022 in parallel with the equivalent teriparatide labeling change, based on accumulated post-marketing surveillance showing no human osteosarcoma signal. The ACTIVExtend trial (Cosman et al., Mayo Clin Proc 2017) demonstrated that patients completing 18 months of abaloparatide and transitioning to alendronate for 24 additional months preserved and extended fracture-risk reduction — the sequential anabolic-then-antiresorptive paradigm that defines modern osteoanabolic practice. Subsequent development produced the ATOM trial (Czerwinski et al., JBMR 2022) establishing efficacy in men with osteoporosis and leading to FDA approval for the male indication, and a transdermal microneedle-patch formulation (abaloparatide-sMTS) that fell short of non-inferiority versus subcutaneous injection but remains under continued development. Abaloparatide sits alongside teriparatide (PTH 1-34) and romosozumab (sclerostin inhibitor) as one of three FDA-approved osteoanabolic agents, and its differentiated pharmacology relative to teriparatide has made it a common choice where high BMD gain at the hip is the clinical priority.

How It Works

Abaloparatide mimics a natural hormone called PTHrP that, when given in once-daily pulses, tells bone-building cells (osteoblasts) to build new bone faster than bone-removing cells (osteoclasts) break it down. It is engineered to produce a cleaner, more transient signal than teriparatide, which translates to strong new-bone gains with less calcium disturbance.

Abaloparatide is a synthetic 34-amino-acid peptide based on the N-terminus of parathyroid hormone-related protein (PTHrP 1-34). Like teriparatide, it activates the PTH1 receptor on osteoblasts, but with a distinct conformational preference: abaloparatide binds preferentially to the RG conformation of PTH1R, whereas PTH 1-34 binds more readily to the R0 conformation. RG binding produces a more transient cAMP/PKA response, which in preclinical and clinical data translates to a larger net anabolic effect relative to osteoclast activation — a wider 'anabolic window.' Downstream, intermittent PTH1R activation drives Wnt/β-catenin signaling, suppresses sclerostin, and promotes osteoblast proliferation, differentiation, and survival. Continuous exposure (as in primary hyperparathyroidism) would be catabolic; the once-daily pulsatile dosing schedule is essential to the anabolic pharmacology. The RG-selective pharmacology is also hypothesized to explain the lower incidence of treatment-emergent hypercalcemia observed with abaloparatide versus teriparatide in the ACTIVE trial.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Abaloparatide:

• 01Head-to-head fracture outcomes versus teriparatide and romosozumab — existing comparisons rely on the open-label teriparatide arm of ACTIVE and on indirect network meta-analyses; dedicated active-comparator fracture-endpoint trials are limited.
• 02Optimal sequencing within the osteoanabolic toolkit — with three anabolic agents now approved (teriparatide, abaloparatide, romosozumab), the best sequence (and whether any are interchangeable within a patient journey) is an evolving question that guideline bodies are still working through.
• 03Long-term post-marketing osteosarcoma surveillance — the 2022 removal of the boxed warning was based on accumulated negative surveillance data, but the very long latency for solid-tumor signals means continued pharmacovigilance is warranted.
• 04Transdermal microneedle-patch development — the 2023 abaloparatide-sMTS Phase 3 trial did not meet non-inferiority versus subcutaneous injection; whether this route can be made comparably effective with design iteration is unresolved.
• 05Real-world adherence and persistence — daily subcutaneous injection therapy adherence is moderate at best in real-world osteoporosis cohorts; predictors of adherence and effective interventions to improve persistence are incompletely characterized for abaloparatide specifically.
• 06Use in glucocorticoid-induced osteoporosis — abaloparatide has not been trialed in this indication to the extent that teriparatide has, leaving a guideline gap where clinicians default to teriparatide by evidence weight rather than mechanistic equivalence.
• 07Repeat-course efficacy — whether patients who complete an initial course, transition to antiresorptive consolidation, and are later considered for a second course derive additional BMD benefit is inadequately studied.

Forms & Administration

Daily subcutaneous injection of 80 mcg via multi-dose prefilled pen device (Tymlos), self-administered into the periumbilical region. Each pen contains 30 days of medication and is refrigerated before first use. First injection should be given with the patient seated or lying down because of orthostatic hypotension risk. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Tymlos (abaloparatide) is FDA-approved for postmenopausal women with osteoporosis at high risk of fracture and for men with osteoporosis at high risk of fracture. It should be prescribed by a clinician experienced in osteoporosis management.

Timeline of Effects

Common Questions

Who Abaloparatide Is NOT For

Drug & Supplement Interactions

Abaloparatide has a relatively simple drug-interaction profile because peptide proteolytic clearance does not engage CYP-mediated metabolism. It does not significantly inhibit or induce major CYP enzymes at therapeutic doses, and is not a clinically significant substrate of common transporters. The clinically important interactions are pharmacodynamic rather than pharmacokinetic. Digoxin: theoretical concern about additive arrhythmia risk from the transient post-dose hypercalcemia; clinical significance is modest but attention is appropriate in patients on digoxin with established cardiac disease. The interaction profile is effectively identical to teriparatide. Loop and thiazide diuretics: thiazides reduce urinary calcium excretion and can compound the transient post-dose hypercalcemia of abaloparatide; serum calcium monitoring in patients on combined therapy is appropriate. Loop diuretics increase calcium excretion and partially counteract the effect. Antihypertensive agents: abaloparatide produces a small transient decrease in supine blood pressure and a small transient increase in heart rate within 1 hour of dosing. Patients on antihypertensives — particularly those at risk of orthostatic hypotension — warrant the first dose administered sitting or lying down and periodic reassessment as the treatment course continues. Glucocorticoids: corticosteroids antagonize the anabolic effect through osteoblast suppression, but abaloparatide still produces meaningful BMD gains in glucocorticoid-treated patients; abaloparatide has not been formally studied in glucocorticoid-induced osteoporosis to the extent that teriparatide has. Bisphosphonates and denosumab: sequential use (abaloparatide first, then bisphosphonate or denosumab) is the established and ACTIVExtend-supported approach. Concurrent use has not been studied in outcome trials and is not standard practice. Calcium and vitamin D: routinely co-administered as supportive care rather than an interacting drug. As with any chronic osteoporosis therapy, all medications including OTC supplements should be disclosed to the prescribing clinician.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions